Gastric Cancer Diagnostic Procedure Global Market Report 2024

The gastric cancer diagnostic procedure market size has grown strongly in recent years. It will grow from $1.32 billion in 2023 to $1.43 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth witnessed in the historical period can be ascribed to advancements in biopsy techniques, augmented research funding, the evolution of biomarker discovery, enhanced pathological analysis, and changes in screening guidelines.

The gastric cancer diagnostic procedure market size is expected to see strong growth in the next few years. It will grow to $1.88 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The anticipated growth in the forecast period can be attributed to an increase in point-of-care testing, the introduction of novel biomarkers, a shift towards personalized medicine, the adoption of next-generation sequencing, and enhanced endoscopic imaging modalities. Major trends expected in the forecast period include the integration of nanotechnology, the adoption of big data analytics, the application of microbiota analysis, increased patient-centric approaches, and the role of telehealth in diagnostics.

The increasing prevalence of gastrointestinal diseases is a driving force behind the anticipated growth in the gastric cancer diagnostic procedure market. Gastrointestinal disorders encompass a range of illnesses affecting various sections of the digestive system and supporting organs, including the liver and pancreas. The gastric cancer diagnostic procedure is essential for addressing stomach cancer through methods such as endoscopy and biopsy. Therefore, the expanding incidence of gastrointestinal diseases is contributing to the market's growth. For instance, a study conducted by GI Associates & Endoscopy Center, a US-based medical facility specializing in gastroenterology services, involved 73,076 people from 33 nations, revealing that 40% of the subjects suffered from a functional gastrointestinal illness in August 2022. Hence, the increasing prevalence of gastrointestinal diseases is a significant factor propelling the growth of the gastric cancer diagnostic procedure market.

The rising prevalence of smoking is expected to drive the growth of the gastric cancer diagnostic procedure market in the future. Smoking involves the inhalation and exhalation of smoke produced by burning tobacco or other substances. Gastric cancer diagnostic procedures play a crucial role for individuals with a history of smoking or those at risk of smoking-related cancers by enabling early detection, identifying precancerous lesions, developing personalized treatment plans, facilitating communication and coordination, and providing a comprehensive assessment of the gastric mucosa and surrounding tissues. According to a report by The World Health Organization, a Switzerland-based intergovernmental organization, in July 2023, more than 8 million people are killed by tobacco each year, including 1.3 million non-smokers who inhale second-hand smoke. Therefore, the rising prevalence of smoking is a key driver of the growth of the gastric cancer diagnostic procedure market.

Technological advancements represent a prominent trend gaining momentum in the gastric cancer diagnostic market. Leading companies in the gastric cancer diagnostic market are actively incorporating new technologies to maintain their competitive positions. For example, in June 2022, Ibex Medical Analytics, an Israel-based provider of AI-powered diagnostics for health organizations, introduced Galen Gastric, the world's first AI-powered solution designed for gastric cancer detection. Galen Gastric serves as an integrated diagnostic tool assisting pathologists in identifying stomach cancer, H. pylori, and other critical clinical findings, contributing to faster turnaround times and improved diagnostic workflows.

Prominent companies in the gastric cancer diagnostic procedure market are strategically focusing on innovative products such as tissue staining platforms to drive revenue growth. The tissue staining platform aims to deliver rapid and precise test results, enabling medical professionals to make timely decisions regarding patient care. In June 2022, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, introduced the benchmark ultra plus system. This system, building on the proven technology of the benchmark ultra system, provides a fully automated workflow for immunohistochemistry (IHC) and in-situ hybridization (ISH) slide staining. It enhances the laboratory experience with features such as a retractable work surface, improved sliding drawers, indicator lights, and remote monitoring via a connected device, addressing user feedback. The system emphasizes efficient workflow, testing efficiency, and eco-friendly attributes.

In April 2021, Amgen, a US-based biopharmaceutical company, completed the acquisition of Five Prime Therapeutics for $1.9 billion. This strategic move enables Amgen to introduce innovative, best-in-class diagnostic products to the market, contributing to the growth of the company's presence in gastric cancer diagnostics and supporting its international expansion strategy. Five Prime Therapeutics, a US-based clinical-stage biotechnology company, specializes in providing gastric cancer diagnostic services.


Major companies operating in the gastric cancer diagnostic procedure market report are Pfizer Inc., Johnson & Johnson Co, F. Hoffmann La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories Inc., Sanofi SA, Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd., AdventHealth, Atrium Health, Astellas Pharma Inc., Bausch Health Companies Inc., Agilent Technologies Inc., Ipsen Pharma, Hartford HealthCare, Myriad Genetics Inc., Myriad Genetics Inc., NovoCure Limited, Foundation Medicine Inc., Biocept Inc.

North America was the largest region in the gastric cancer diagnostics procedure market in 2023. The regions covered in the gastric cancer diagnostic procedure market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer diagnostic procedure market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Key procedures in the diagnostic process for gastric cancer include endoscopic procedures, biopsies, tissue tests, laboratory tests, in-vitro diagnostic tests, imaging tests, molecular diagnostics, multiplexing molecular diagnostics, immunoassays, and others. The endoscopic procedure involves the examination of internal organs, such as the gastrointestinal tract, by inserting a long, thin tube directly into the body. This endoscopy procedure is utilized in gastric cancer diagnosis, addressing both symptomatic and asymptomatic cases, and encompasses instruments, reagents and consumables, and services. Various body fluids, including blood, urine, saliva, stomach juice, and tissue, are required for the procedure. These fluids aid in the detection and treatment of both early and advanced gastric cancer.

The gastric cancer diagnostic procedure market research report is one of a series of new reports that provides gastric cancer diagnostic procedure market statistics, including the gastric cancer diagnostic procedure industry's global market size, regional shares, competitors with a gastric cancer diagnostic procedure market share, detailed gastric cancer diagnostic procedure market segments, market trends, and opportunities, and any further data you may need to thrive in the gastric cancer diagnostic procedure industry. This gastric cancer diagnostic procedure market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastric cancer diagnostics procedure market includes revenues earned by entities that provide diagnostic procedures such as surgery, chemotherapy, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.